期刊文献+

罗格列酮对2型糖尿病大鼠肾皮质趋化因子fractalkine表达的影响

Effect of rosiglitazone on the expression of fractalkine in renal cortex of type 2 diabetic rats
原文传递
导出
摘要 目的 观察罗格列酮对2型糖尿病大鼠肾皮质趋化因子fractalkine表达的影响.方法 SD大鼠30只,10只分至正常对照组,20只腹腔注射小剂量链脲佐菌素结合高能量饲料制备2型糖尿病大鼠模型,然后分至糖尿病组(n=10)及罗格列酮干预组(n=10).运用流动注射分析法测定血清糖基化终产物-肽(advanced glycosylation end products-peptide,AGE-P),应用半定量逆转录聚合酶链反应和免疫组织化学法分别检测肾皮质fractalkine mRNA和蛋白表达.选用单因素方差分析进行数据统计分析.结果 糖尿病组大鼠血清AGE-P[(2.87±0.21)U/ml]、肾皮质fractalkine mRNA(1.41±0.03)及fractalkine蛋白表达(0.79±0.04)均明显高于对照组[分别为(0.90±0.13)U/ml、0.85±0.04及0.46±0.03,P<0.01];罗格列酮干预组大鼠血清AGE-P[(1.45±0.15)U/ml]、肾皮质fractalkine mRNA(1.00±0.05)及fractalkine蛋白表达(0.67±0.03)则明显低于糖尿病组(P<0.01).结论 罗格列酮可能通过抑制肾皮质fractalkine表达发挥其肾脏保护作用. Objective To investigate the effect of rosiglitazone on the expression of fractalkine in renal cortex of type 2 diabetic rats. Methods Thirty Sprague-Dawley (SD)rats were randomly divided into normal control group (n=10) and type 2 diabetic model groups which were induced by intraperitoneal injection of low-dose streptozotocin combined with high fat diet. After diabetes established, diabetic rats were then randomized to receive rosiglitazone (n = 10) or vehicle (n=10) treatment. Serum advanced glycosylation end products-peptide (AGE-P) was measured by using flow injection assay. The mRNA and protein expressions of fractalkine were detected by semi-quantitative reverse transcription polymerase chain reaction and immunohistochemical staining, respectively. One-way analysis of variances was used for data analysis. Results The serum AGE-P [(2.87±0.21) U/ml], and the expression of fractalkine mRNA (1.41±0. 03) and protein (0. 79±0.04) in the renal cortex were significantly higher in the diabetes group than the normal control group [(0.90±0.13) U/ml, 0.85±0.04, and 0.46±0.03; P<0.01].However, the serum AGE-P [(1.45±0.15) U/ml], and the expression of fractalkine mRNA (1.00± 0. 05) and protein (0. 67±0.03) in the rosiglitazone group were significantly lower compared to the diabetes group (P < 0.01). Conclusions Rosiglitazone may have renoprotective effects via inhibiting fractalkine expression in the renal cortex.
出处 《中华糖尿病杂志》 CAS 2009年第2期-,共4页 CHINESE JOURNAL OF DIABETES MELLITUS
基金 教育部留学回国人员科研启动基金,无锡市科技基金
  • 相关文献

参考文献11

  • 1Bakris G,Viberti G,Weston WM. Rosiglitazone reduces urinary albumin excretion in type Ⅱ diabetes[J].Journal of HUMAN HYPERTENSION,2003,(1):7-12.doi:10.1038/sj.jhh.1001444.
  • 2魏琼,董莉,孙子林,刘必成,刘乃丰.罗格列酮对糖基化终产物干预的人肾系膜细胞fractalkine表达的影响[J].中华内分泌代谢杂志,2008,24(6):660-661. 被引量:5
  • 3郭啸华,刘志红,李恒,朱加明,黎磊石.实验性2型糖尿病大鼠模型的建立[J].肾脏病与透析肾移植杂志,2000,9(4):351-355. 被引量:210
  • 4Zilin S,Naifeng L,Bicheng L. The determination of AGE-peptides by flow injection assay,a practical marker of diabetic nephropathy[J].Clinica Chimica Acta,2001,(1/2):69-75.doi:10.1016/S0009-8981(01)00651-9.
  • 5郑茂,叶山东,陈燕,范爱红,王迎新,钱燕,林杨,何媛媛,李秀财,杨光伟,陈柯.罗格列酮保护糖尿病大鼠肾损害及其抗炎机制的实验研究[J].中国医科大学学报,2008,37(3):334-336. 被引量:8
  • 6Segerer S,Hughes E,Hudkin KL. Expression of the fractalkine receptor (CX3CR1) in human kidney diseases[J].Kidney International,2002.488-495.doi:10.1046/j.1523-1755.2002.00480.x.
  • 7Cockwell P,Chakravorty SJ,Girdlestone J. Fractalkine expression in human renal inflammation[J].Journal of Pathology,2002.85-90.
  • 8Kikuchi Y,Ikee R,Herami N. Fractalkine and its receptor,CX3CR1,upregulation in streptozotocin-induced diabetic kidneys[J].Nephron Experimental Nephrology,2004.e17-e25.
  • 9Wang G,Wei J,Guan Y. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty[J].Metabolism-Clinical and experimental,2005.590-597.
  • 10Lombardi A,Cantini G,Piscitelli E. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells[J].Arteriosclerosis,Thrombosis,and Vascular Biology,2008,(4):718-724.doi:10.1161/ATVBAHA.107.160713.

二级参考文献15

  • 1李慧,邹大进,贾一韬,韦多,季军捷,彭玲.罗格列酮对高糖诱导的大鼠系膜细胞NF-κB活性及MCP-1表达的抑制作用[J].中华内分泌代谢杂志,2005,21(5):469-470. 被引量:7
  • 2Thomas MC, Forbes JM, Cooper ME. Advanced glycation end products and diabetic nephropathy. Am J Ther, 2005,12:562-572.
  • 3Katherine RT. Linking metabolism and immunology : diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol, 2005,16: 1537-1538.
  • 4Sun ZL. AGE induce the expression of monocyte chemoattractant protein- 1 in human renal mesangial cells. Diabetologia, 2002,45:A394.
  • 5Kikuchi Y, Imakiire T, Hyodo T, et al. Advanced glycation end-product induces fractalkine gene upregulation in normal rat glomeruli. Nephrol Dial Transplant, 2005,20:2690-2696.
  • 6Kikuchi Y, Ikee R, Hemmi N, et al. Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys. Nephron Exp Nephrol, 2004,97 :e17-e25.
  • 7Moraes LA, Piqueras L, Bishop BD. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther, 2006,110:371-385.
  • 8Luo J,Metabolism,1998年,47卷,663页
  • 9Storlien L H,Ann NY Acad Sci,1993年,683卷,57页
  • 10Hwang I S,Hypertension,1987年,10卷,512页

共引文献220

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部